Scilex Holding Company Receivables, Net, Current
Scilex Holding Company (SCLX) had Receivables, Net, Current of $3.20 million as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesNetCurrent · last filed 2025-03-31
- 2024-12-31: Receivables, Net, Current $3.20M.
- 2024-09-30: Receivables, Net, Current $3.20M.
- 2024-06-30: Receivables, Net, Current $3.20M.
- 2024-03-31: Receivables, Net, Current $3.20M.
| Period end | Receivables, Net, Current |
|---|---|
| 2024-12-31 | $3.20M 10-K · filed 2025-03-31 |
| 2024-09-30 | $3.20M 10-Q · filed 2025-01-17 |
| 2024-06-30 | $3.20M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $3.20M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $3.20M 10-K · filed 2024-03-12 |
| 2023-09-30 | $3.20M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.20M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $3.20M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |